AGTC to Host Third Quarter Financial Results Conference Call and Webcast on May 7, 2019
Get Alerts AGTC Hot Sheet
Join SI Premium – FREE
GAINESVILLE, Fla. and CAMBRIDGE, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial results for the fiscal quarter ended March 31, 2019 before the market opens on Tuesday, May 7, 2019. AGTC management will host a conference call beginning at 8:00 AM Eastern Time that day to review results and provide a corporate update.
To access the call, dial 877-407-6184 (US) or 201-389-0877 (outside of the US). A live webcast will be available in the Events and Presentations section of the Investor Relations page at http://ir.agtc.com/events-and-presentations. Please log in approximately 10 minutes prior to the scheduled start time. The archived webcast will be available in the Events and Presentations section of the company's website.
About AGTC
AGTC is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa (XLRP), achromatopsia (ACHM CNGB3 & ACHM CNGA3) and X-linked retinoschisis (XLRS). In addition to its clinical trials, AGTC has preclinical programs in optogenetics, adrenoleukodystrophy (ALD), which is a disease of the central nervous system (CNS), other ophthalmology and otology indications. The optogenetics program is being developed in collaboration with Bionic Sight. In addition to its product pipeline, AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as expertise in the formulation, manufacture and physical delivery of gene therapy products.
IR/PR CONTACTS: David Carey (IR) or Tom Vickery (PR) Lazar Partners Ltd. T: (212) 867-1768 or (646) 871-8482 [email protected] or [email protected]
Corporate Contacts: Bill Sullivan Chief Financial Officer Applied Genetic Technologies Corporation T: (617) 843-5728 [email protected]
Stephen Potter Chief Business Officer Applied Genetic Technologies Corporation T: (617) 413-2754 [email protected]
Source: Applied Genetic Technologies CorporationSerious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- Inter Parfums (IPAR) PT Lowered to $172 at Piper Sandler
- CEMEX, S.A.B. de C.V. (CX) Tops Q1 EPS by 5c
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!